Cargando…

Once‐Daily Oxycodone Prolonged‐Release Tablets Are Resistant to Alcohol‐Induced Dose Dumping: Results From a Randomized Trial in Healthy Volunteers

The objective of this study was to determine the effect of concomitant alcohol intake on the bioavailability of oxycodone from an oxycodone once‐daily (OOD) formulation and an oxycodone twice‐daily (OTD) formulation. A phase I, open‐label, randomized, crossover alcohol interaction study in 20 health...

Descripción completa

Detalles Bibliográficos
Autores principales:	Burger, Nils, Fraser, Douglas, Maritz, Martina Alice, Faulkner, Janice, Rey, Helene
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	John Wiley and Sons Inc. 2020
Materias:	Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7214637/ https://www.ncbi.nlm.nih.gov/pubmed/32027446 http://dx.doi.org/10.1111/cts.12737

Ejemplares similares

Bioavailability of oxycodone after administration of a new prolonged-release once-daily tablet formulation in healthy subjects, in comparison to an established twice-daily tablet
por: Scheidel, Bernhard, et al.
Publicado: (2017)

Design and in vivo evaluation of oxycodone once-a-day controlled-release tablets
por: Kim, Ju-Young, et al.
Publicado: (2015)

Effectiveness and Safety of Once-Daily Extended-Release Hydrocodone in Individuals Previously Receiving Immediate-Release Oxycodone for Chronic Pain
por: Pergolizzi, Joseph, et al.
Publicado: (2018)

Formulation and Evaluation of Once Daily Minocycline Hydrochloride Extended Release Matrix Tablets
por: Keny, R. V., et al.
Publicado: (2009)

Effects of Renal Impairment on the Pharmacokinetics of Once-Daily Amantadine Extended-Release Tablets
por: deVries, Tina, et al.
Publicado: (2019)

Long-term safety and efficacy of oxycodone/naloxone prolonged-release tablets in patients with moderate-to-severe chronic cancer pain
por: Ahmedzai, Sam H., et al.
Publicado: (2014)

Comparison of once-daily versus twice-daily combination of Ropinirole prolonged release in Parkinson’s disease
por: Yun, Ji Young, et al.
Publicado: (2013)

ENhANCE trial protocol: A multi-centre, randomised, phase IV trial comparing the efficacy of oxycodone/naloxone prolonged release (OXN PR) versus oxycodone prolonged release (Oxy PR) tablets in patients with advanced cancer
por: Wong, Aaron K., et al.
Publicado: (2022)

Bioavailability and Pharmacokinetics of Once-Daily Amantadine Extended-Release Tablets in Healthy Volunteers: Results from Three Randomized, Crossover, Open-Label, Phase 1 Studies
por: deVries, Tina, et al.
Publicado: (2019)

Pharmacokinetics of Once‐Daily Extended‐Release Tacrolimus Tablets Versus Twice‐Daily Capsules in De Novo Liver Transplant
por: DuBay, Derek A., et al.
Publicado: (2019)

Colorectal Transit and Volume During Treatment With Prolonged-release Oxycodone/Naloxone Versus Oxycodone Plus Macrogol 3350
por: Poulsen, Jakob L, et al.
Publicado: (2018)

HIV virologic response better with single-tablet once daily regimens compared to multiple-tablet daily regimens
por: Kapadia, Shashi N, et al.
Publicado: (2018)

A Comparison of Daily Average Consumption (DACON) of Oxycodone and Oxymorphone Long-Acting Oral Tablets
por: Rubino, Mark, et al.
Publicado: (2011)

Pain therapy with oxycodone/naloxone prolonged-release combination: case report
por: Błaszczyk, Feliks, et al.
Publicado: (2013)

Intractable restless legs syndrome: role of prolonged-release oxycodone–naloxone
por: de Biase, Stefano, et al.
Publicado: (2016)

Methodological Issues on a Clinical Trial to Test Tapentadol Prolonged release vs. Oxycodone/Naloxone Prolonged release
por: Bacallao, Jorge, et al.
Publicado: (2016)

A phase III randomized controlled study on the efficacy and improved bowel function of prolonged‐release (PR) oxycodone‐naloxone (up to 160/80 mg daily) vs oxycodone PR
por: Dupoiron, D., et al.
Publicado: (2017)

Pooled post hoc analysis of population pharmacokinetics of oxycodone and acetaminophen following a single oral dose of biphasic immediate-release/extended-release oxycodone/acetaminophen tablets
por: Franke, Ryan M, et al.
Publicado: (2015)

Bioavailability of Melatonin after Administration of an Oral Prolonged-Release Tablet and an Immediate-Release Sublingual Spray in Healthy Male Volunteers
por: Ait Abdellah, Samira, et al.
Publicado: (2023)

Tacrolimus Exposure Before and After a Switch From Twice-Daily Immediate-Release to Once-Daily Prolonged Release Tacrolimus: The ENVARSWITCH Study
por: Monchaud, Caroline, et al.
Publicado: (2023)

Evaluation of Flexible Tacrolimus Drug Concentration Monitoring Approach in Patients Receiving Extended‐Release Once‐Daily Tacrolimus Tablets
por: Philosophe, Benjamin, et al.
Publicado: (2018)

Tolerability and safety of gastroretentive once-daily gabapentin tablets for the treatment of postherpetic neuralgia
por: Irving, Gordon A, et al.
Publicado: (2012)

Evaluation and Optimization of Prolonged Release Mucoadhesive Tablets of Dexamethasone for Wound Healing: In Vitro–In Vivo Profiling in Healthy Volunteers
por: Javed, Qurrat ul Ain, et al.
Publicado: (2022)

Cost-effectiveness of the once-daily efavirenz/emtricitabine/tenofovir tablet compared with the once-daily elvitegravir/cobicistat/emtricitabine/tenofovir tablet as first-line antiretroviral therapy in HIV-infected adults in the US
por: Juday, Timothy, et al.
Publicado: (2013)

Among once-daily regimens, single tablet regimens (STRs) are associated with better adherence
por: Murri, R, et al.
Publicado: (2012)

Tacrolimus dose adjustment is not necessary in dose to dose conversion from a twice daily to a prolonged release once daily dose form
por: Tiankanon, Kanitha, et al.
Publicado: (2022)

A randomized cross-over comparison of short-term exposure of once-daily extended release tacrolimus and twice-daily tacrolimus on renal function in healthy volunteers
por: Zaltzman, Jeffrey S, et al.
Publicado: (2014)

Short- and Long-term Outcomes of De Novo Liver Transplant Patients Treated With Once-Daily Prolonged-Release Tacrolimus
por: Okumura, Yuichiro, et al.
Publicado: (2017)

Bioequivalence Study of Modified-Release Gliclazide Tablets in Healthy Volunteers
por: Rojanasthien, Noppamas, et al.
Publicado: (2012)

A Multicenter, Prospective, Observational Study of Conversion from Twice-Daily Immediate-Release to Once-Daily Prolonged-Release Tacrolimus in Liver Transplant Recipients in France: The COBALT Study
por: Dumortier, Jérôme, et al.
Publicado: (2019)

Effectiveness and tolerance of single tablet versus once daily multiple tablet regimens as first-line antiretroviral therapy - Results from a large french multicenter cohort study
por: Cotte, Laurent, et al.
Publicado: (2017)

Effects of oxycodone hydrochloride sustained-release tablets and morphine hydrochloride sustained-release tablets on peripheral blood T cell levels in advanced lung squamous cell carcinoma with moderate to severe cancer pain
por: Yan, Juan, et al.
Publicado: (2023)

Prolonged-Release Once-Daily Formulation of Tacrolimus Versus Standard-of-Care Tacrolimus in de novo Kidney Transplant Patients Across Europe
por: Budde, Klemens, et al.
Publicado: (2022)

Twice-Daily versus Once-Daily Pramipexole Extended Release Dosage Regimens in Parkinson's Disease
por: Yun, Ji Young, et al.
Publicado: (2017)

Long-term efficacy and safety of combined prolonged-release oxycodone and naloxone in the management of non-cancer chronic pain
por: Sandner-Kiesling, A, et al.
Publicado: (2010)

Efficacy and tolerability of low-dose oral prolonged-release oxycodone/naloxone for chronic nononcological pain in older patients
por: Guerriero, Fabio, et al.
Publicado: (2014)

Analgesic Efficacy and Safety of Prolonged-Release Oxycodone/Naloxone in Korean Patients with Chronic Pain from Spinal Disorders
por: Hwang, Chang Ju, et al.
Publicado: (2018)

Oxycodone Controlled Release in Cancer Pain Management
por: Biancofiore, Giuseppe
Publicado: (2006)

Twice‐Daily Doravirine Overcomes the Interaction Effect from Once‐Weekly Rifapentine and Isoniazid in Healthy Volunteers
por: Lam, Edwin, et al.
Publicado: (2020)

A randomized, double-blind, active-controlled, double-dummy, parallel-group study to determine the safety and efficacy of oxycodone/naloxone prolonged-release tablets in patients with moderate/severe, chronic cancer pain
por: Ahmedzai, Sam H, et al.
Publicado: (2012)

Cannot write session to /tmp/vufind_sessions/sess_ld77qkrju3uu12q2m749pu1ou3